| Name | Title | Contact Details |
|---|---|---|
Scott McMillan |
Chief Technical Officer | Profile |
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium
Imperial Clinical Research Services is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Liphatech is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.